Krikler D M
Br J Clin Pharmacol. 1986;21 Suppl 2(Suppl 2):183S-189S. doi: 10.1111/j.1365-2125.1986.tb02869.x.
The antiarrhythmic effects of verapamil were observed before it was appreciated that it was a calcium ion-antagonist. Intravenous verapamil is highly effective in the termination of paroxysmal reciprocating atrioventricular tachycardia, whether associated with preexcitation or involving the atrioventricular node alone. It consistently slows and regularises the ventricular response in atrial fibrillation, and usually increases the degree of AV-nodal block in atrial flutter though it occasionally induces a return to sinus rhythm. Given orally it is useful for the prophylaxis of atrioventricular reentry tachycardia, and also in modulating the atrioventricular nodal response in atrial fibrillation. Favourable response in ventricular tachycardia is exceptional and then seen in specific benign varieties. Verapamil is the agent of choice for the termination of paroxysmal supraventricular tachycardia.
在维拉帕米被认识到是一种钙离子拮抗剂之前,其抗心律失常作用就已被观察到。静脉注射维拉帕米对于终止阵发性折返性房室性心动过速非常有效,无论其是否与预激相关或仅累及房室结。它能持续减慢房颤时的心室反应并使其规律化,并且通常会增加房扑时房室结阻滞的程度,尽管它偶尔会诱发恢复窦性心律。口服时,它对预防房室折返性心动过速有用,也可用于调节房颤时的房室结反应。在室性心动过速中出现良好反应的情况很罕见,仅在特定的良性类型中可见。维拉帕米是终止阵发性室上性心动过速的首选药物。